Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer
Trial ID or NCT#
NCT06080061
Status
RECRUITING
Purpose
The purpose of this study is to examine the use of hypofractionated accelerated radiation therapy (HART) to treat locally advanced lung cancer. Depending on the location and size of the tumor.
Official Title
Phase I Trial of Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer
Eligibility Criteria
Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
- - Histologically or cytologically documented malignancy of the lung including non-small cell lung cancer or small cell lung cancer planned for definitive therapy with fractionated radiation (60-66 Gy) and concurrent systemic therapy - ECOG performance status of 0-2 - Age > 18 years old - Ability to understand and the willingness to personally sign the written IRB approved informed consent document - Estimated life expectancy of 12 weeks or longer
Exclusion Criteria:
- - Contraindication to receiving radiotherapy or systemic therapy as determined by treating radiation and medical oncologist - Age < 18 years old - Tumor directly invading the major pulmonary arteries, aorta, heart or proximal bronchial tree - Diagnosis of interstitial pulmonary fibrosis - Previous radiation therapy to the thorax that would result in overlapping high dose radiation fields
Investigator(s)
Lucas Kas Vitzthum, MD
Radiation oncologist
Clinical Associate Professor, Radiation Oncology - Radiation Therapy
Contact us to find out if this trial is right for you.
Contact
Aneesh Swamy
650-498-8495
View on ClinicalTrials.gov
